The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia

• DOI: 10.1185/03007990802177150
• Publication Date: 2008-06-27T00:52:34Z
• Authors: E. S. Nakou; T. D. Filippatos; M. Georgoula; D. N. Kiortsis; A. D. Tselepis; D. P. Mikhailidis; M. S. Elisaf
• Keywords: Orlistat; Ezetimibe; Lipid Profile; Dyslipidemia

Background: Increased concentrations of low density lipoprotein cholesterol (LDL-C), as well small dense LDL-C (sdLDL-C), are considered cardiovascular risk factors.Objective: An assessment the effects ezetimibe and orlistat administration, alone or in combination, on sdLDL-C levels (primary endpoint), anthropometric variables metabolic parameters (secondary endpoints) overweight obese patients [body mass index (BMI) > 28 kg/m2] with hypercholesterolaemia [total 200 mg/dL (5.2 mmol/L)].Methods: Eighty six subjects were prescribed a low-fat low-calorie diet randomly allocated to receive 120 mg, 3 times daily (O group), 10 mg/day (E group) both (OE for 6 months.Results: Significant reductions (−19%, −21%, −32% groups O, E OE, respectively, all p < 0.01 vs. baseline) (−45%, −48%, −76% E, observed. Group OE experienced significantly greater reduction compared O (p 0.05). Furthermore, significant BMI, homeostasis model (HOMA) index, serum uric acid, transaminase activities plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) activity observed groups. Gamma-glutamyl transpeptidase Lp-PLA2 improved more combination treatment either monotherapy.Conclusions: Orlistat had favourable effect hypercholesterolaemic than drug alone. orlistat, ezetimibe, additionally several variables.